Michèle Beau-Faller, MD, PhD, on NSCLC: Biomarker Findings From the  French Cooperative Thoracic Intergroup 
    		2017 ESMO Congress
    	
    	
    	
    
        Michèle Beau-Faller, MD, PhD, of the Hôpital de Hautepierre & Institut Régional du Cancer, discusses study results on ultrasensitive detection of EGFR T790M mutation by droplet digital PCR in TKI naïve non–small cell lung cancer harboring EGFR mutation (Abstract 85PD).
    
    
    
    
       
       
    		
		
		
        
		
		
		
		Robert A. Figlin, MD, of Cedars-Sinai Medical Center, discusses an interim analysis of phase III findings on rocapuldencel-T, an individualized immunotherapy, for newly diagnosed patients with metastatic renal cell carcinoma (Abstract 1137O).
			
			
     	
    
       
       
    		
		
		
        
		
		
		
		Jaafar Bennouna, MD, of the University of Nantes, discusses findings from a phase II French study of bevacizumab or cetuximab plus chemotherapy after progression with bevacizumab plus chemotherapy in patients with wild-type KRAS metastatic colorectal cancer (Abstract 477O).
			
			
     	
    
       
       
    		
		
		
        
		
		
		
		Eric Pujade-Lauraine, MD, PhD, of the Université Paris Descartes, discusses phase III study findings on the efficacy of olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer by lines of prior chemotherapy (Abstract 932PD).
			
			
     	
    
       
       
    		
		
		
        
		
		
		
		Robert I. Haddad, MD, of Dana-Farber Cancer Institute, discusses phase III study results on treatment beyond disease progression with nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (Abstract 1043O).
			
			
     	
    
       
       
    		
		
		
        
		
		
		
		Simone Koole, MD (and a PhD candidate), of the Netherlands Cancer Institute, discusses phase III findings on health-related quality of life after hyperthermic intraperitoneal chemotherapy for stage III ovarian cancer.